Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that it contracted with Imaging Endpoints in Arizona so as to conduct radiologic imaging that will be needed for company’s Phase 2b clinical trial targeting pancreatic cancer. It is the first news in a series of announcements that company plans to announce pertaining to the company’s planned Phase IIb clinical study, including a full plan of the dramatically enhanced clinical trial design. The study will assess the effectiveness of Pharmacyte’s pancreatic cancer treatment in patients with this disease.
In last trading session, the stock price of Pharmacyte jumped more than 3% to close the trading session at $0.0940.The gains came at a share volume of 1.13 million compared to monthly average share volume of 1.45 million.
Uluru Inc (OTCMKTS:ULUR) stated that in the last quarter, the company revealed promising interim results for the pharmaco-economic evaluation process being performed in Europe. The delightful news came from Russia as the company obtained marketing approval for the Altrazeal sale by the governing bodies of Russia. Also, the company commenced the shipment of Altrazeal for markets of Egypt and Saudi Arabia.
ULURU is included in the list of specialty pharmaceutical companies focused on the advancement of oral care as well as wound management products. On Wednesday, the stock price of Uluru plunged more than 15% to close the trading session at $0.270. The drop came at a share volume of 44,453 compared to average share volume of 15,808.
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) revealed that it introduced Alevicyn SG Antipruritic Spray Gel targeting for pain and Itching problems in Atopic Dermatitis. The spray gel is formulated with the advanced Microcyn Technology and effectively relives the pain, itching and other problems experienced by people suffering with dermatoses, like atopic and radiation dermatitis.
On Wednesday, the stock price of Oculus gained 0.87% to close the trading session at $1.16.